AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration

Bioanalysis

Volumn 3, Issue 4, 2011, Pages 393-405

  Lappin, Graham ^a   Seymour, Mark ^a   Young, Graeme ^b   Higton, David ^c   Hill, Howard M ^d  

^a Xceleron Ltd   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d HUNTINGDON LIFE SCIENCES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DRUG;

ACCELERATOR MASS SPECTROMETRY; ACCURACY; CALIBRATION; CHROMATOGRAPHY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG FORMULATION; DRUG MICRODOSE; DRUG SAFETY; DRUG SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ION CURRENT; ISOTOPE DILUTION ASSAY; LIQUID CHROMATOGRAPHY; LIQUID SCINTILLATION COUNTING; MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; REVIEW; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

DRUG ADMINISTRATION ROUTES; GOVERNMENT REGULATION; HUMANS; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; VEINS;

EID: 79952011378     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.5     Document Type: Review

References (19)

1. Lappin G, Rowland M, Garner RC. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin. Drug Metab. Toxicol. 2(3), 419-427 (2006). (Pubitemid 46141407)
2. Lappin G, Shishikura Y, Jochemsen R et al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur. J. Pharm. Sci. 40, 125-131 (2010).
3. Strong JM, Dutcher JS, Lee WK, Atkinson AJ Jr. Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method. Clin. Pharmacol. Ther. 18(5 Pt 1), 613-622 (1975).
4. Barker J, Garner RC. Biomedical applications of accelerator mass spectrometry - isotope measurements at the level of the atom. Rapid Commun. Mass Spectrom. 13(4), 285-293 (1999). (Pubitemid 29101097)
5. Dueker SR, Lohstroh PN, Giacomom JA, Keck BD. Human ADME using microdoses and microtracers: bioanalytical considerations. Bioanalysis 2(3), 441-454 (2010).
6. ICH Topic M3: Note for Guidance on nonclinical safety pharmacology studies for human pharmaceuticals. CPMP/ICH/286/95 (December 2009).
7. Lappin G, Stevens L. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 4(8), 1021-1033 (2008).
8. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Centre for Veterinary Medicine. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD, USA, May 2001.
9. Fast DM, Kelley M, Viswanathan CT et al. Workshop report and follow-up - AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples - implications of Crystal City recommendations. AAPS J. 11(2), 238-241 (2009).
10. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007). (Pubitemid 47389236)
11. Keck BD, Ognibebe T, Vogel JS. Analytical validation of accelerator mass spectrometry for pharmaceutical development. Bioanalysis 2(3), 469-485 (2010).
12. Vogel J, Love AH. Quantitating isotopic molecular labels with accelerator mass spectrometry. In:Methods in Enzymology . Burlingame AL (Ed.). Academic Press, NY, USA (2005).
13. Salehpour M, Possnert G, Bryhni H. Subattomole sensitivity in biological accelerator mass spectrometry. Anal. Chem. 80(10), 3515-3521 (2008). (Pubitemid 351705849)
14. Lappin G, Simpson M, Shishikura Y, Garner C. High-performance liquid chromatography accelerator massspectrometry: correcting for losses during analysis by internal standardization. Anal. Biochem. 378, 93-95 (2008).
15. Salehpour M, Possnert G, Bryhni H, Palminger-Hallen I, Stahle L. Biological accelerator mass spectrometry at Uppsala University. Appl. Radiat. Isot. 67(3), 495-499 (2007).
16. Zoppi U, Crye J, Song Q, Arjomand A. Performance evaluation of the new AMS system at Accium Biosciences. Radiocarbon 49(1), 173-182 (2007).
17. Gao L, Chowdhury S, Alton K et al. Application of accelerator mass spectrometry in microdose absolute bioavailability studies. Presented at: the 11th Annual Land O'Lakes Bioanalytical Conference. Merrimac, WI, USA, 19-23 July 2010.
18. Young G, Ellis W, Ayrton J, Hussey E, Adamkiewicz B. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 31(8-9), 619-632 (2001). (Pubitemid 32826395)
19. EMEA draft Guidance on Bioanalysis, November 2009.